Zacks Investment Research downgraded shares of Gemphire Therapeutics Inc. (NASDAQ:GEMP) from a hold rating to a sell rating in a research note released on Tuesday.
According to Zacks, “Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company’s product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. “
Other analysts also recently issued reports about the stock. HC Wainwright started coverage on shares of Gemphire Therapeutics in a research report on Thursday, August 31st. They set a buy rating and a $21.00 price objective on the stock. Canaccord Genuity set a $31.00 price objective on shares of Gemphire Therapeutics and gave the company a buy rating in a research report on Monday, August 14th. Finally, Jefferies Group LLC cut their price objective on shares of Gemphire Therapeutics from $32.00 to $18.00 and set a buy rating on the stock in a research report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $24.40.
Gemphire Therapeutics (NASDAQ:GEMP) last announced its quarterly earnings data on Monday, August 14th. The company reported ($0.99) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.28).
TRADEMARK VIOLATION WARNING: “Gemphire Therapeutics Inc. (GEMP) Cut to “Sell” at Zacks Investment Research” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://sportsperspectives.com/2017/10/13/gemphire-therapeutics-inc-gemp-cut-to-sell-at-zacks-investment-research.html.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Northpointe Capital LLC purchased a new stake in shares of Gemphire Therapeutics during the 2nd quarter valued at about $3,472,000. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Gemphire Therapeutics by 1.7% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 153,064 shares of the company’s stock valued at $1,959,000 after acquiring an additional 2,500 shares during the last quarter. GM Advisory Group Inc. purchased a new stake in shares of Gemphire Therapeutics during the 2nd quarter valued at about $457,000. Vanguard Group Inc. boosted its holdings in shares of Gemphire Therapeutics by 137.6% during the 2nd quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock valued at $399,000 after acquiring an additional 17,892 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Gemphire Therapeutics during the 1st quarter valued at about $184,000. 29.70% of the stock is currently owned by hedge funds and other institutional investors.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.